Evidence map›Paper›PMID 41922440›Full record

ArticleScientific reports2026

Urolithin A blocks colorectal cancer progression by AKT1 inhibition-driven immune activation.

Ziquan Sun, Jingtao Li, Hongsheng Chen, Zhongxu Zhang, Yingnan Zhang, Yang Wang, Zewen Chang, Fangfang Bi, Jiaojiao Dong, Zhongsheng Chen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ziquan Sun *Department of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Jingtao Li *Department of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Hongsheng Chen *Department of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Zhongxu ZhangDepartment of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Yingnan ZhangHeilongjiang Provincial Key Laboratory of Digestive Surgery and Nutrition & Metabolism, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Yang WangHeilongjiang Provincial Key Laboratory of Digestive Surgery and Nutrition & Metabolism, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Zewen ChangDepartment of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Fangfang BiHeilongjiang Provincial Key Laboratory of Digestive Surgery and Nutrition & Metabolism, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Jiaojiao DongDepartment of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Zhongsheng ChenDepartment of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Ming LiuDepartment of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. mingliu35@hrbmu.edu.cn.

Funding

Excellent youth project of the Fourth Affiliated Hospital of Harbin Medical University Grant No.HYDSYYXQN2023004Heilongjiang Provincial Postdoctoral Fund Grant No.LBH-Z24223the basic Scientific Research Project of Provincial Universities in Heilongjiang Province, China 2023-KYYWF-0235the project of the Fourth Affiliated Hospital of Harbin Medical University Grant No.KYJB2024-04
6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most common and lethal malignancies worldwide, with its initiation and progression closely linked to metabolic reprogramming, abnormal cell proliferation, and immune evasion. Urolithin A (UA), a natural polyphenol with favorable oral safety and bioavailability, has been reported to exert antitumor effects through metabolic regulation and immune modulation. In this study, we combined network pharmacology, molecular docking, and single-cell transcriptomics to explore the potential anticancer mechanisms of UA, which were further examined through in vitro and in vivo experiments. UA was found to be associated with AKT1-related signaling and dose-dependently suppressed the proliferation, migration, and invasion of CRC cell lines, including HCT15, HCT116, and MC38. At appropriate concentrations, UA further enhanced CD8

Indexed as

Colorectal NeoplasmsCoumarinsProto-Oncogene Proteins c-aktAnimalsCD8-Positive T-LymphocytesCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleHumansMiceSignal TransductionTOR Serine-Threonine Kinases3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneAKT1 protein, humanCoumarinsProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesAKT1Colorectal cancerImmune modulationUrolithin A

Identifiers

PMID41922440
PMCPMC13184318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.